# To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA

> **NCT06436911** · PHASE1,PHASE2 · COMPLETED · sponsor: **Entos Pharmaceuticals Inc.** · enrollment: 46 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** COVIGENIX VAX- 002

## Key facts

- **NCT ID:** NCT06436911
- **Lead sponsor:** Entos Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-22
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06436911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06436911, "To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06436911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*